Kazia Therapeutics

Kazia Therapeutics Ltd. is a clinical stage oncology company It engages in the pharmaceutical research and development business. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

Australia-based Kazia Therapeutics Limited (NASDAQ: KZIA) announced final data from a Phase 2 study of paxalisib as first-line therapy in patients with glioblastoma. 60mg once daily was identified as the maximum tolerated dose (MTD) and selected for future studies.

Kazia Unveils Final Data From Mid-Stage Paxalisib Data In Newly Diagnosed Glioblastoma Patients

Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA), a cancer-focused drug development company based in Sydney, has released final data from its Phase 2 clinical study of the drug paxalisib – a first-line therapy in patients with glioblastoma. The company reports that these results confirm the asset's previously reported safety and efficacy markers, and the company has high hopes that this signals a breakthrough in the treatment of a complex disease of “high unmet need".

Kazia Therapeutics releases positive final data from Phase 2 trial of glioblastoma treatment paxalisib, shares up

SYDNEY, Nov. 29, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to inform stakeholders that the GBM AGILE study in glioblastoma (NCT03970447) has opened at Sunnybrook Health Sciences Centre in Toronto, Ontario. This marks the first Canadian site to open to paxalisib, and the first opportunity for Canadian patients to access the drug.

GBM AGILE Opens to Paxalisib in Canada

Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA)'s cancer drug, paxalisib, which targets glioblastoma, will now reach patients in Canada through a new study at Sunnybrook Health Sciences Centre in Toronto, Ontario. The company's flagship drug, paxalisib, is a candidate in GBM AGILE, a multi-drug platform study designed to identify promising new therapies for glioblastoma.

Kazia Therapeutics expands further in North America with Toronto glioblastoma study

SYDNEY, Nov. 15, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the appointment of John Friend, MD, as Chief Medical Officer. In this role, Dr. Friend will be responsible for overseeing the development and commercialization of Kazia's pipeline drug candidates, and for collaborating with clinicians and scientists to advance the company's research programs.

Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer

Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) has appointed John Friend MD, the former chief medical officer (CMO) at Cellectar Biosciences (NASDAQ:CLRB), Inc as its new CMO.  Dr Friend will be responsible for overseeing the development and commercialization of Kazia's pipeline drug candidates, and collaborate with clinicians and scientists to advance the company's research programs.

Kazia Therapeutics appoints former Cellectar Biosciences chief medical officer John Friend as new CMO

SYDNEY, Nov. 11, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that PNOC022 (NCT05009992), a multi-drug phase II study in DIPG and diffuse midline gliomas, has been initiated at the University of California, San Francisco, with the first patient successfully enrolled to the study. PNOC022 includes Kazia's investigational drug, paxalisib among the experimental arms and is expected to provide valuable data on the potential use of the drug in this highly aggressive form of childhood brain cancer.

PNOC Study in Childhood Brain Cancer Enrols First Patient

Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA)'s investigational drug paxalisib is playing a role in PNOC022, a multi-drug phase II study in DIPG and diffuse midline gliomas, that has been initiated at the University of California, San Francisco, with the first patient enrolled to the study. Diffuse intrinsic pontine glioma (DIPG) is the most common of a group of childhood brain cancers known as diffuse midline gliomas (DMGs).

Kazia Therapeutics welcomes start of PNOC study in childhood brain cancer, first patient enrolled

SYDNEY, Nov. 4, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it has commenced enrolment to a phase I clinical trial of EVT801, an investigational cancer therapy that Kazia licensed from Evotec SE in April 2021. Key Points EVT801 is a small molecule inhibitor of VEGFR3, and acts by inhibiting lymphangiogenesis, the formation of new lymphatic vessels around the tumour.

Kazia Enrols First Patient to EVT801 Phase I Clinical Trial

Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) has officially enrolled its first patient in its investigational cancer therapy trial. The oncology-focused drug development company licensed the cancer therapy, known as EVT801, from German biotech Evotec AG in April 2021.

Kazia Therapeutics enrols first patient to phase I clinical trial of EVT801 cancer therapy

Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) has received the nod from two research houses, with the Maxim Group LLC initiating coverage with a ‘buy' recommendation and Edison increasing its valuation to A$2.83 from A$2.68 per basic share.   The Maxim Group has also put a 12-month target price of US$18 per American Depository Share (ADS), which is also listed on NASDAQ.

Kazia Therapeutics gets boost with ‘buy' call from Maxim Group and valuation upgrade from Edison

Kazia Therapeutics Ltd has received an increased target price share from Edison Group, rising to A$2.83 from A$2.68 a share following the release of interim data for its 30-patient Phase II trial of paxalisib in newly diagnosed glioblastoma multiforme (GBM) patients. Final data from the trial as well as initial data for paxalisib in the treatment of brain metastases (BMs) is expected before the end of this year.

Kazia Therapeutics' paxalisib program data garners increased target share price of A$2.83 from Edison

SYDNEY, Oct. 6, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the LD Micro Main Event, to be held virtually and in person from 12-14 October 2021. Since 2008, the LD Micro Main Event has established itself as one of the leading conferences for small-cap companies across a wide range of sectors.

Kazia Therapeutics to Present at LD Micro Main Event

SYDNEY, Sept. 10, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the HC Wainwright 23rd Annual Global Investment Conference, to be held virtually from 13-15 September 2021.

Kazia Therapeutics to Present at HC Wainwright 23rd Annual Global Investment Conference

Kazia Therapeutics Ltd has received full regulatory approval for its planned phase 1 study for EVT801 from L'Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), the French regulatory agency. Kazia, an oncology-focused drug development company, licensed EVT801 from Evotec SE, an international drug discovery alliance and development partnership company, in April 2021.

Kazia Therapeutics receives full regulatory approval for EVT801 phase 1 study

Kazia Therapeutics Ltd directors Dr James Garner and Iain Ross have shown their faith in the company's oncology-focused drug development strategy by acquiring shares on-market. Dr Garner, who is chief executive officer and an executive director, acquired 20,000 shares in two lots of 10,000 for total consideration of around $27,500 on August 27, 2021.

Kazia Therapeutics directors support oncology-focused drug strategy with on-market purchases

Kazia Therapeutics Ltd will define its future success by commercialisation revenue, with US$323 million in potential milestone payments from outbound partnering deals awaiting its brain cancer drug paxalisib and legacy asset Cantrixil. Kazia on Thursday released its annual report, capping off a “game-changing” 2021 financial year for the oncology drug developer in which it reported a maiden revenue of A$15.18 million.

Kazia Therapeutics eyeing commercialisation revenue after “game-changing” FY21

Kazia Therapeutics Ltd has had a “busy and productive” June quarter as it makes great strides with the paxalisib clinical program, including the launch of two new studies.  The oncology-focused drug development company is also expecting a number of important read-outs targeted for the second half of the year.

Kazia Therapeutics has 'busy and productive' June quarter with important readouts slated for second half

SYDNEY, July 21, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a leading drug development company in the field of brain cancer, today recognizes Glioblastoma (GBM) Awareness Day and calls for a greater focus on research from industry, academia, and government in order to better treat the disease. GBM is the most common and most aggressive form of primary brain cancer, and it is expected that approximately 13,000 Americans will receive a GBM diagnosis in 2021.

Kazia Calls for Increased Focus on Brain Cancer Research this GBM Awareness Day

SYDNEY , June 30, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update on recent progress with its two pipeline assets, paxalisib and EVT801. Key Points GBM AGILE pivotal study of paxalisib is recruiting ahead of expectations, with almost 25 sites now open to the paxalisib arm.

Kazia Provides Progress Update on Paxalisib and EVT801 Clinical Programs

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) has made strong progress in the first half of 2021 with its oncology-focused drug development program, including the pipeline assets of paxalisib and EVT801. The GBM AGILE pivotal study of paxalisib is recruiting ahead of expectations, with almost 25 sites now open to the paxalisib arm in the United States across several prestigious centres.

Kazia Therapeutics makes strong progress with clinical programs for paxalisib and EVT801

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) has secured manufacturing patents for its paxalisib cancer treatment candidate in key territories, extending its patent protection out until 2036. The oncology-focused drug development company has been awarded manufacturing patents in the US and India, while a similar patent has progressed in Australia and is on track to be granted in the coming quarter.

Kazia Therapeutics lands key manufacturing patents for paxalisib in US and India

SYDNEY, June 15, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it has entered a collaboration with the Joan & Sanford I Weill Medical College of Cornell University in the United States, to launch a phase II clinical study investigating the use of Kazia's investigational new drug, paxalisib, in combination with ketogenesis, for glioblastoma. Key Points Research by Professor Lew Cantley, who discovered the PI3K pathway, suggests that ketogenesis may enhance the activity of PI3K inhibitors in glioblastoma, with impressive preclinical data previously published in Nature Ketogenesis represents an alternative biochemical mechanism in which the body is fueled by fats and proteins rather than by glucose; it occurs in states such as starvation, and also in response to a 'ketogenic diet' Data from this study has the potential to significantly enhance the activity of paxalisib in glioblastoma, and to minimize certain side effects, including hyperglycemia (high blood sugar) Dr Howard Fine, founding Director of the Brain Tumor Center at New York-Presbyterian Weill Cornell Medical Center, will serve as Principal Investigator; Professor Cantley will be a scientific advisor to the study Kazia will provide support including study drug and a financial grant Dr Fine, Principal Investigator to the study, commented, "glioblastoma remains an immensely challenging disease, and we need the most potent array of tools at our disposal in order to treat it.

Kazia Enters Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With Ketogenic Diet for Glioblastoma

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) has teamed up with a medical college from Cornell University to launch a phase two clinical study investigating Kazia's investigational new drug paxalisib in combination with ketogenesis. Specifically, the study will evaluate Kazia's paxalisib candidate, in combination with ketogenesis, for treating an aggressive form of cancer known as glioblastoma.

Kazia Therapeutics to collaborate with Cornell University for new paxalisib phase II clinical trial

SYDNEY, June 7, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia's investigational new drug, paxalisib, in primary CNS lymphoma has been initiated at Dana-Farber Cancer Institute, with the first patient successfully enrolled to the study. Key Points Lymphoma is a cancer of white blood cells.

News for Kazia Therapeutics Stock (KZIA)